annb0t
Top 20
MELBOURNE, Australia, June 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)Â today announces that the first patient has been dosed in a Phase II study of the Company's carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of cancer indications. (PRNewsfoto/Telix Pharmaceuticals Limited)
The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospe...
>>> Read more: First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospe...
>>> Read more: First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
